บันทึกจากแหล่งปฐมภูมิ
ระดับชี้ขาดผลลัพธ์ topline
Tempest รายงานอัตรา CR 100% สำหรับ TPST-2003 ใน rrMM
The 8-K reports positive interim Phase 1/2a data from REDEEM-1 and POEMS-1 trials showing a 100% complete response rate in all 15 CAR-T-naïve efficacy-evaluable patients treated with TPST-2003. The data also highlight a favorable safety profile with no Grade ≥3 CRS or ICANS and prior median PFS of 23.1 months. These results support the planned initiation of a U.S. registrational study later this year.
ข้อเท็จจริงสำคัญ
ข้อความจากแหล่งที่มา
EX-99.1 2 tpst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempest Reports First Quarter 2026 Financial Results and Provides Business Update Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of Business Development Brisbane, CA , May 14, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. “We made strong pro